EP
CRNX icon

Elkfork Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Elkfork Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$4K Hold
280
– – ﹤0.01% 1052
2019
Q2 		$7K Hold
280
– – ﹤0.01% 1046
2019
Q1 		$6K Buy
+280
New +$6.88K ﹤0.01% 1032

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Elkfork Partners's CRNX Position: Q3 2019 in Review

Elkfork Partners held its Crinetics Pharmaceuticals (CRNX) position steady in Q3 2019 at 280 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

Elkfork Partners first reported a position in CRNX in Q1 2019 and has held it in 3 quarters since. The position peaked at $7K in Q2 2019. 61 funds tracked by Wall St. Rank hold CRNX as of Q3 2019.

  • Elkfork Partners held 280 shares of Crinetics Pharmaceuticals worth $4K as of Q3 2019.
  • Elkfork Partners left its Crinetics Pharmaceuticals share count unchanged in Q3 2019.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1052 holding.
  • Elkfork Partners first reported a position in Crinetics Pharmaceuticals in Q1 2019 and has held it in 3 quarters since.
  • Elkfork Partners's Crinetics Pharmaceuticals position peaked at $7K in Q2 2019.
  • 61 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.